Posted by Michael Wonder on 25 Apr 2018
European Commission approves Bristol-Myers Squibb’s Opdivo (nivolumab) four-week dosing schedule for advanced melanoma and previously treated renal cell carcinoma
25 April 2018 - Opdivo also now approved for two-week flat dose option with 30 minute infusions across all approved monotherapy indications in the EU.
Bristol-Myers Squibb today announced that the European Commission (EC) has approved an every four week (Q4W) Opdivo (nivolumab) monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced melanoma and previously treated renal cell carcinoma.
The EC also approved a two week (Q2W) Opdivo dosing option of 240 mg infused over 30 minutes to replace weight-based dosing for all six approved monotherapy indications in the EU.
